CRPCa - formerly known as hormone-refractory PCa - is considered a progression of disease despite medical or surgical castration. The Prostate Cancer Working Group 2 introduced the term CRPCa in 2008 to characterise clinical and/or biochemical advancement within a castration environment.3,4
The European Association of Urology (EAU) defines CRPCa as: Castrate serum testosterone <1.7nmol/L plus either:1
- Biochemical progression: Three consecutive rises in PSA at least one week apart resulting in two 50% increases over the nadir, and a PSA...
